Trial reportMolecular imaging and biology2012
P-glycoprotein function at the blood-brain barrier: effects of age and gender.
Trial report in Molecular imaging and biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 147 citations in OpenAlex.
- Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[British journal of clinical pharmacology · 2017Trial
- Article
- Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy.Molecular pharmaceutics · 2026Article
- Potential Links Between Aging, Mitochondrial Dysfunction, and Drug Transporter Function-Molecular Mechanisms and Pharmacokinetic Implications.International journal of molecular sciences · 2026Review
- Evaluating sex as a biological variable in in vitro blood-brain barrier models: insights from primary mouse brain endothelial cells.Fluids and barriers of the CNS · 2026Article
- Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.Frontiers in immunology · 2026Review
- Differential Risks of Dementia, Depression, and Injury Among Common α-Blockers, with Tamsulosin as the Reference Drug: A Real-World Cohort Study in Men with Lower Urinary Tract Symptoms.Journal of clinical medicine · 2025Article
- Measurement of cyclosporin induced changes in P-glycoprotein function at the human blood-brain barrier using [European journal of nuclear medicine and molecular imaging · 2025Article
- Molecular Aspects of Geriatric Pharmacotherapy.Cells · 2025Review
- Exploratory Study of Sex Differences in P-Glycoprotein Function at the Blood-Brain Barrier.Clinical and translational science · 2025Article
- The pathobiology of neurovascular aging.Neuron · 2025Review
- Multiregional blood-brain barrier phenotyping identifies the prefrontal cortex as the most vulnerable region to ageing in mice.Brain communications · 2025Article
- Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.Current pharmaceutical design · 2025Review
- Circadian Rhythms of the Blood-Brain Barrier and Drug Delivery.Circulation research · 2024Review
- Quantification of P-glycoprotein function at the human blood-brain barrier using [European journal of nuclear medicine and molecular imaging · 2023Article
- Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women.Translational psychiatry · 2023Article
- Proteomic alterations in the brain and blood-brain barrier during brain Aβ accumulation in an APP knock-in mouse model of Alzheimer's disease.Fluids and barriers of the CNS · 2023Article
- Generation and characterization of a zebrafish knockout model of abcb4, a homolog of the human multidrug efflux transporter P-glycoprotein.Human genomics · 2023Article
- ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery.Pharmacological reviews · 2023Review
- Generation and characterization of a zebrafish knockout model of abcb4, a homolog of the human multidrug efflux transporter P-glycoprotein.Research square · 2023Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeP-glycoprotein (Pgp) is an efflux transporter involved in transport of several compounds across the blood-brain barrier (BBB). Loss of Pgp function with increasing age may be involved in the development of age-related disorders, but this may differ between males and females. Pgp function can be quantified in vivo using (R)-[(11)C]verapamil and positron emission tomography. The purpose of this study was to assess global and regional effects of both age and gender on BBB Pgp function. PROCEDURES: Thirty-five healthy men and women in three different age groups were included. Sixty minutes dynamic (R)-[(11)C]verapamil scans with metabolite-corrected arterial plasma input curves were acquired. Grey matter time-activity curves were fitted to a validated constrained two-tissue compartment plasma input model, providing the volume of distribution (V (T)) of (R)-[(11)C]verapamil as outcome measure.
resultsIncreased V (T) of (R)-[(11)C]verapamil with aging was found in several large brain regions in men. Young and elderly women showed comparable V (T) values. Young women had higher V (T) compared with young men.
conclusionsDecreased BBB Pgp is found with aging; however, effects of age on BBB Pgp function differ between men and women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.